ClinicalTrials.gg
CompletedNCT02666664Updated May 11, 2020Results posted

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

A Phase 3 interventional study of ETC-1002 and Placebo in Hypercholesterolemia and Atherosclerotic Cardiovascular Diseases, sponsored by Esperion Therapeutics, Inc.. Completed at 104 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-11.

Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
Largest of 21
2,230 · median 126
Started
2016
with 3 others
Phase 3
7 of 21
1 open now
Registered
7th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one has the largest enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 7th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to see if ETC-1002 (bempedoic acid) is safe and well-tolerated versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.

03

Conditions studied

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Diseases

Keywords

  • hyperlipidemia
  • cholesterol
  • heterozygous familial hypercholesterolemia
  • atherosclerotic cardiovascular disease
  • ASCVD
  • HeFH
  • LDL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-C ≥ 70 mg/dL
  • High cardiovascular risk (diagnosis of HeFH or ASCVD)
  • Be on maximally tolerated lipid-modifying therapy

Exclusion criteria

Exclusion Criteria:

  • Total fasting triglyceride ≥500 mg/dL
  • Renal dysfunction or nephrotic syndrome or history of nephritis
  • (BMI) ≥50kg/m2
  • Significant cardiovascular disease or cardiovascular event in the past 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,230 participants (actual)

Study arms

  • Experimental
    ETC-1002

    ETC-1002 180 mg/day

    Drug: ETC-1002

  • Placebo comparator
    Placebo

    Placebo control

    Drug: Placebo

Interventions

  • ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)

    Also known as: bempedoic acid

  • DrugPlacebo

    Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs, defined as adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported.

    Time frame: Up to approximately 52 weeks

  2. Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event

    TEAEs, defined as AEs that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported. Cardiovascular events were considered as adverse events of special interest. Treatment-emergent = TE.

    Time frame: Up to approximately 52 weeks

  3. Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations

    TEAEs of special interest (AESIs) were predefined and monitored throughout the study. Creatine kinase elevations were assessed using the following preferred term: Blood creatine phosphokinase increased (system organ class: investigations).

    Time frame: Up to approximately 52 weeks

  4. Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders

    Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to hepatic events were assessed using the following preferred terms and laboratory abnormalities: aspartate aminotransferase (AST) increased, Alanine aminotransferase (ALT) increased, Hepatic enzyme increased, Blood bilirubin increased, liver function test (LFT) abnormal, LFT increased, hepatic enzyme abnormal, transaminases increased, potential Hy's Law cases (PHLC) \[AST and (\&)/or ALT \>3 x upper limit of normal (ULN) with concurrent total bilirubin \>2 x ULN\], AST and/or ALT \>3 x ULN, and total bilirubin \>2 x ULN (system organ class: investigations). AST and ALT values were repeated and confirmed. "Repeated and confirmed" was defined as a participant having the last on-study LFT \> x ULN, the last on-treatment LFT \> x ULN, or LFT \> x ULN followed by another LFT \> x ULN.

    Time frame: Up to approximately 52 weeks

  5. Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia

    Treatment-emergent AESIs were predefined and monitored throughout the study. Hypoglycemia was assessed using the following preferred terms: hypoglycaemia (system organ class: metabolism and nutrition disorders); blood glucose abnormal and blood glucose decreased (system organ class: investigations). The percentage of unique participants is reported in the "Overall hypoglycemia AESIs" category; a participant could have been represented in more than one of the individual hypoglycemia AESIs.

    Time frame: Up to approximately 52 weeks

  6. Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis

    Treatment-emergent AESIs were predefined and monitored throughout the study. Metabolic acidosis was assessed using the preferred term metabolic acidosis (system organ class: metabolism and nutrition disorders).

    Time frame: Up to approximately 52 weeks

  7. Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder

    Treatment-emergent AESIs were predefined and monitored throughout the study. Muscular safety was assessed using the following preferred terms and laboratory abnormalities: myalgia, muscle spasms, pain in extremity, muscular weakness (system organ class: musculoskeletal and connective tissue disorders), and creatine kinase \>5 ULN (repeated and confirmed). The percentage of unique participants is reported in the "Overall muscular disorder AESIs" category; a participant could have been represented in more than one of the individual muscular disorder AESIs.

    Time frame: Up to approximately 52 weeks

  8. Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder

    Treatment-emergent AESIs were predefined and monitored throughout the study. Neurocognitive disorder was assessed using the following preferred terms: memory impairment, amnesia, and cognitive disorder (system organ class: nervous system disorders); confusional state and disorientation (system organ class: psychiatric disorders). The percentage of unique participants is reported in the "Overall neurocognitive disorder AESIs" category; a participant could have been represented in more than one of the individual neurocognitive disorder AESIs.

    Time frame: Up to approximately 52 weeks

  9. Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus

    Treatment-emergent AESIs were predefined and monitored throughout the study. New onset or worsening diabetes was assessed using the following preferred terms: type 2 diabetes mellitus, diabetes mellitus, hyperglycaemia, glucose tolerance impaired, diabetes mellitus inadequate control, and impaired fasting glucose (system organ class: metabolism and nutrition disorders); blood glucose increased, glycosylated haemoglobin increased, blood glucose abnormal, and glucose urine present (system organ class: investigations); and glycosuria (system organ class: renal and urinary disorders). The percentage of unique participants is reported in the "Overall new onset/worsening diabetes mellitus AESIs" category; a participant could have been represented in more than one of the individual new onset/worsening diabetes mellitus AESIs.

    Time frame: Up to approximately 52 weeks

  10. Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder

    Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to renal events were assessed using the following preferred terms: renal failure, renal impairment, acute kidney injury (system organ class: renal and urinary disorders); blood creatinine increased, glomerular filtration rate decreased, blood urea increased, estimated glomerular filtration rate (eGFR) \<30 milliliter per minute per 1.73 square meter (ml/min/1.73m\^2), and change from baseline in creatinine \>1 mg/dL (system organ class: investigations); and gout (system organ class: metabolism and nutrition disorders). The percentage of unique participants is reported in the "Overall renal disorder AESIs" category; a participant could have been represented in more than one of the individual renal disorder AESIs.

    Time frame: Up to approximately 52 weeks

  11. Change From Baseline to Week 52 in Uric Acid (Urate) Level

    Blood samples were drawn at defined time points during the course of the study to monitor uric acid (urate) levels.

    Time frame: Baseline and Week 52

  12. Change From Baseline to Week 52 in Creatinine Level

    Blood samples were drawn at defined time points during the course of the study to monitor creatinine levels.

    Time frame: Baseline and Week 52

  13. Change From Baseline to Week 52 in Hemoglobin Level

    Blood samples were drawn at defined time points during the course of the study to monitor hemoglobin levels.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Least Square mean= LS mean. Percent change was analyzed using the analysis of covariance (ANCOVA) method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 12

  2. Absolute Change From Baseline to Week 12 in LDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Absolute change from baseline was calculated as: LDL-C value at Week 12 minus Baseline value. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen.

    Time frame: Baseline; Week 12

Other outcomes

  1. Percent Change From Baseline to Week 24 in LDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 24

  2. Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 12

  3. Percent Change From Baseline to Week 12 in Total Cholesterol (TC)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 12

  4. Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 12

  5. Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 12

  6. Percent Change From Baseline to Week 52 in LDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

    Time frame: Baseline; Week 52

  7. Percent Change From Baseline to Week 24 in Non-HDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 24

  8. Percent Change From Baseline to Week 52 in Non-HDL-C

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 52

  9. Percent Change From Baseline to Week 24 in TC

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 24

  10. Percent Change From Baseline to Week 52 in TC

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 52

  11. Percent Change From Baseline to Week 24 in apoB

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed

    Time frame: Baseline; Week 24

  12. Percent Change From Baseline to Week 52 in apoB

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 52

  13. Percent Change From Baseline to Week 24 in hsCRP

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 24

  14. Percent Change From Baseline to Week 52 in hsCRP

    Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Baseline; Week 52

  15. Percentage of Participants Achieving LDL-C <70 mg/dL at Week 12, 24, and 52

    The percentage of participants who achieved lowering in lipid values of LDL-C below 70 mg/dL have been reported. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Observed data was used for the analysis, no imputation for the missing data was performed.

    Time frame: Week 12, Week 24, and Week 52

07

Results

Posted Apr 20, 2020

Participant flow

A total of 2230 participants were randomized 2:1 to either bempedoic acid or placebo. One participant was randomized to bempedoic acid treatment, but never received any dose of investigational medicinal product (IMP) i.e. study drug.

Participant flow — Overall Study
MilestonePlaceboBempedoic Acid
Started7421488
Completed7061404
Not completed3684
Withdrew: Physician decision01
Withdrew: Protocol violation02
Withdrew: Other01
Withdrew: Adverse event1237
Withdrew: Withdrawal by participant2340
Withdrew: Sponsor decision01
Withdrew: Lost to follow-up12

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs, defined as adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsPlaceboBempedoic Acid
Any TEAE78.778.5
Any serious TEAE14.014.5
Any fatal TEAE0.30.9
Any TEAE leading to discontinuation of study drug7.110.9
PrimaryPercentage of Participants With Adjudicated Major Adverse Cardiovascular Event

TEAEs, defined as AEs that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were collected and reported. Cardiovascular events were considered as adverse events of special interest. Treatment-emergent = TE.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event
percentage of participantsPlaceboBempedoic Acid
Any adjudicated major clinical event5.74.6
Any TE death from cardiovascular causes0.10.4
Any nonfatal myocardial infarction1.81.3
Any nonfatal stroke0.30.3
Any coronary revascularization3.22.6
Any hospitalization for unstable angina1.50.9
TE death from noncardiovascular causes0.10.1
Noncoronary arterial revascularization0.80.3
Hospitalization for heart failure0.10.6
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations

TEAEs of special interest (AESIs) were predefined and monitored throughout the study. Creatine kinase elevations were assessed using the following preferred term: Blood creatine phosphokinase increased (system organ class: investigations).

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations
percentage of participantsPlaceboBempedoic Acid
Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations1.82.4
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders

Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to hepatic events were assessed using the following preferred terms and laboratory abnormalities: aspartate aminotransferase (AST) increased, Alanine aminotransferase (ALT) increased, Hepatic enzyme increased, Blood bilirubin increased, liver function test (LFT) abnormal, LFT increased, hepatic enzyme abnormal, transaminases increased, potential Hy's Law cases (PHLC) \[AST and (\&)/or ALT \>3 x upper limit of normal (ULN) with concurrent total bilirubin \>2 x ULN\], AST and/or ALT \>3 x ULN, and total bilirubin \>2 x ULN (system organ class: investigations). AST and ALT values were repeated and confirmed. "Repeated and confirmed" was defined as a participant having the last on-study LFT \> x ULN, the last on-treatment LFT \> x ULN, or LFT \> x ULN followed by another LFT \> x ULN.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders
percentage of participantsPlaceboBempedoic Acid
Overall hepatic disorder AESIs1.52.5
AST increased0.41.5
ALT increased0.30.8
Hepatic enzyme increased0.00.5
Blood bilirubin increased0.40.1
Liver function test abnormal0.30.1
Liver function test increased0.10.2
Hepatic enzyme abnormal0.00.1
Transaminases increased0.10.0
PHLC [AST &/or ALT>3 x ULN, concurrent TB>2 x ULN]0.00.0
AST and/or ALT >3 x ULN0.10.5
Total bilirubin >2 x ULN0.00.0
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Hypoglycemia

Treatment-emergent AESIs were predefined and monitored throughout the study. Hypoglycemia was assessed using the following preferred terms: hypoglycaemia (system organ class: metabolism and nutrition disorders); blood glucose abnormal and blood glucose decreased (system organ class: investigations). The percentage of unique participants is reported in the "Overall hypoglycemia AESIs" category; a participant could have been represented in more than one of the individual hypoglycemia AESIs.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia
percentage of participantsPlaceboBempedoic Acid
Overall hypoglycemia AESIs3.12.2
Hypoglycaemia3.02.2
Blood glucose abnormal0.10.1
Blood glucose decreased0.00.1
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis

Treatment-emergent AESIs were predefined and monitored throughout the study. Metabolic acidosis was assessed using the preferred term metabolic acidosis (system organ class: metabolism and nutrition disorders).

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis
percentage of participantsPlaceboBempedoic Acid
Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis0.00.1
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Muscular Disorder

Treatment-emergent AESIs were predefined and monitored throughout the study. Muscular safety was assessed using the following preferred terms and laboratory abnormalities: myalgia, muscle spasms, pain in extremity, muscular weakness (system organ class: musculoskeletal and connective tissue disorders), and creatine kinase \>5 ULN (repeated and confirmed). The percentage of unique participants is reported in the "Overall muscular disorder AESIs" category; a participant could have been represented in more than one of the individual muscular disorder AESIs.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder
percentage of participantsPlaceboBempedoic Acid
Overall muscular disorder AESIs10.113.1
Myalgia6.16.0
Muscle spasms2.74.2
Pain in extremity2.23.4
Muscular weakness0.50.6
Creatine kinase >5 ULN0.10.5
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder

Treatment-emergent AESIs were predefined and monitored throughout the study. Neurocognitive disorder was assessed using the following preferred terms: memory impairment, amnesia, and cognitive disorder (system organ class: nervous system disorders); confusional state and disorientation (system organ class: psychiatric disorders). The percentage of unique participants is reported in the "Overall neurocognitive disorder AESIs" category; a participant could have been represented in more than one of the individual neurocognitive disorder AESIs.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder
percentage of participantsPlaceboBempedoic Acid
Overall neurocognitive disorder AESIs0.90.7
Memory impairment0.50.3
Amnesia0.40.2
Cognitive disorder0.00.1
Confusional state0.00.1
Disorientation0.00.1
PrimaryPercentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus

Treatment-emergent AESIs were predefined and monitored throughout the study. New onset or worsening diabetes was assessed using the following preferred terms: type 2 diabetes mellitus, diabetes mellitus, hyperglycaemia, glucose tolerance impaired, diabetes mellitus inadequate control, and impaired fasting glucose (system organ class: metabolism and nutrition disorders); blood glucose increased, glycosylated haemoglobin increased, blood glucose abnormal, and glucose urine present (system organ class: investigations); and glycosuria (system organ class: renal and urinary disorders). The percentage of unique participants is reported in the "Overall new onset/worsening diabetes mellitus AESIs" category; a participant could have been represented in more than one of the individual new onset/worsening diabetes mellitus AESIs.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus
percentage of participantsPlaceboBempedoic Acid
Overall new onset/worsening diabetes mellitus AESI5.43.3
Type 2 diabetes mellitus0.91.0
Diabetes mellitus0.90.4
Hyperglycaemia0.70.5
Glucose tolerance impaired0.10.4
Diabetes mellitus inadequate control0.40.1
Impaired fasting glucose0.30.1
Blood glucose increased1.20.7
Glycosylated haemoglobin increased0.50.0
Blood glucose abnormal0.10.1
Glucose urine present0.10.0
Glycosuria0.30.1
PrimaryPercentage of Participants With the Indicated Event of Special Interest: Renal Disorder

Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to renal events were assessed using the following preferred terms: renal failure, renal impairment, acute kidney injury (system organ class: renal and urinary disorders); blood creatinine increased, glomerular filtration rate decreased, blood urea increased, estimated glomerular filtration rate (eGFR) \<30 milliliter per minute per 1.73 square meter (ml/min/1.73m\^2), and change from baseline in creatinine \>1 mg/dL (system organ class: investigations); and gout (system organ class: metabolism and nutrition disorders). The percentage of unique participants is reported in the "Overall renal disorder AESIs" category; a participant could have been represented in more than one of the individual renal disorder AESIs.

Time frame:
Up to approximately 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder
percentage of participantsPlaceboBempedoic Acid
Renal failure0.10.9
Renal impairment0.10.4
Acute kidney injury0.30.3
Blood creatinine increased0.40.8
Glomerular filtration rate decreased0.00.5
Blood urea increased0.10.1
Gout0.31.2
Change from baseline in creatinine >1 mg/dL0.00.1
eGFR <30 mL/min/1.73 m^20.40.9
PrimaryChange From Baseline to Week 52 in Uric Acid (Urate) Level

Blood samples were drawn at defined time points during the course of the study to monitor uric acid (urate) levels.

Time frame:
Baseline and Week 52
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline to Week 52 in Uric Acid (Urate) Level
milligrams per deciliter (mg/dL)PlaceboBempedoic Acid
Baseline5.96 ± 1.356.06 ± 1.37
Change from Baseline at Week 52-0.06 ± 0.870.73 ± 1.11
PrimaryChange From Baseline to Week 52 in Creatinine Level

Blood samples were drawn at defined time points during the course of the study to monitor creatinine levels.

Time frame:
Baseline and Week 52
Reported as:
Mean · mg/dL
Change From Baseline to Week 52 in Creatinine Level
mg/dLPlaceboBempedoic Acid
Baseline0.96 ± 0.220.97 ± 0.22
Change from Baseline at Week 52-0.02 ± 0.120.02 ± 0.13
PrimaryChange From Baseline to Week 52 in Hemoglobin Level

Blood samples were drawn at defined time points during the course of the study to monitor hemoglobin levels.

Time frame:
Baseline and Week 52
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline to Week 52 in Hemoglobin Level
grams per deciliter (g/dL)PlaceboBempedoic Acid
Baseline14.07 ± 1.2614.22 ± 1.26
Change from Baseline at Week 52-0.23 ± 0.85-0.58 ± 0.88
SecondaryPercent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Least Square mean= LS mean. Percent change was analyzed using the analysis of covariance (ANCOVA) method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)1.6 ± 0.86-16.5 ± 0.52
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -18.1 · 95% CI -20 to -16.1
SecondaryAbsolute Change From Baseline to Week 12 in LDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Absolute change from baseline was calculated as: LDL-C value at Week 12 minus Baseline value. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen.

Time frame:
Baseline; Week 12
Reported as:
Mean · mg/dL
Absolute Change From Baseline to Week 12 in LDL-C
mg/dLPlaceboBempedoic Acid
Absolute Change From Baseline to Week 12 in LDL-C0.43 ± 27.04-19.23 ± 24.01
Other pre-specifiedPercent Change From Baseline to Week 24 in LDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 24 in LDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in LDL-C1.2 ± 0.88-14.9 ± 0.60
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -16.1 · 95% CI -18.2 to -14
Other pre-specifiedPercent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)1.5 ± 0.76-11.9 ± 0.48
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -13.3 · 95% CI -15.1 to -11.6
Other pre-specifiedPercent Change From Baseline to Week 12 in Total Cholesterol (TC)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Total Cholesterol (TC)0.8 ± 0.57-10.3 ± 0.37
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -11.1 · 95% CI -12.5 to -9.8
Other pre-specifiedPercent Change From Baseline to Week 12 in Apolipoprotein B (apoB)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Missing data were imputed with the use of a pattern-mixture model to account for adherence to the trial regimen. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)3.3 ± 0.70-8.6 ± 0.47
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -11.9 · 95% CI -13.6 to -10.2
Other pre-specifiedPercent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 12 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)2.6 ± 91.9-22.4 ± 72.5
Statistical analysis
  • Placebo vs Bempedoic Acid · Wilcoxon (Mann-Whitney) · p = <0.001 · Location shift: -21.5 · 95% CI -26.96 to -16
Other pre-specifiedPercent Change From Baseline to Week 52 in LDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(LDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed. Percent change was analyzed using the ANCOVA method, which included treatment, randomization stratum as factors, and baseline value as covariate.

Time frame:
Baseline; Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline to Week 52 in LDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in LDL-C1.0 ± 0.92-12.6 ± 0.66
Statistical analysis
  • Placebo vs Bempedoic Acid · ANCOVA · p = <0.001 · Difference in ls mean: -13.6 · 95% CI -15.8 to -11.3
Other pre-specifiedPercent Change From Baseline to Week 24 in Non-HDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in Non-HDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in Non-HDL-C1.61 ± 20.91-11.69 ± 19.80
Other pre-specifiedPercent Change From Baseline to Week 52 in Non-HDL-C

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(non-HDL-C value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 52
Reported as:
Mean · percent change
Percent Change From Baseline to Week 52 in Non-HDL-C
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in Non-HDL-C0.65 ± 21.438-10.07 ± 22.097
Other pre-specifiedPercent Change From Baseline to Week 24 in TC

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in TC
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in TC1.15 ± 15.349-9.86 ± 15.358
Other pre-specifiedPercent Change From Baseline to Week 52 in TC

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Percent change from baseline was calculated as: \[(TC value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 52
Reported as:
Mean · percent change
Percent Change From Baseline to Week 52 in TC
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in TC0.38 ± 16.180-8.92 ± 16.945
Other pre-specifiedPercent Change From Baseline to Week 24 in apoB

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed

Time frame:
Baseline; Week 24
Reported as:
Mean · percent change
Percent Change From Baseline to Week 24 in apoB
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in apoB4.8 ± 20.41-7.1 ± 20.01
Other pre-specifiedPercent Change From Baseline to Week 52 in apoB

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apoB. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(apoB value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 52
Reported as:
Mean · percent change
Percent Change From Baseline to Week 52 in apoB
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in apoB3.4 ± 20.24-6.0 ± 22.54
Other pre-specifiedPercent Change From Baseline to Week 24 in hsCRP

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 24 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 24
Reported as:
Median · percent change
Percent Change From Baseline to Week 24 in hsCRP
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 24 in hsCRP2.727 (-33.028 to 59.016)-16.382 (-51.329 to 34.436)
Other pre-specifiedPercent Change From Baseline to Week 52 in hsCRP

Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the last value prior to first dose of study drug. Percent change from baseline was calculated as: \[(hsCRP value at Week 52 minus Baseline value) divided by (Baseline Value)\] multiplied by 100. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Baseline; Week 52
Reported as:
Median · percent change
Percent Change From Baseline to Week 52 in hsCRP
percent changePlaceboBempedoic Acid
Percent Change From Baseline to Week 52 in hsCRP1.818 (-36.508 to 60.952)-14.445 (-50.000 to 43.889)
Other pre-specifiedPercentage of Participants Achieving LDL-C <70 mg/dL at Week 12, 24, and 52

The percentage of participants who achieved lowering in lipid values of LDL-C below 70 mg/dL have been reported. Baseline was defined as the mean of the values at screening (Week -2) and predose Day 1/Week 0. Observed data was used for the analysis, no imputation for the missing data was performed.

Time frame:
Week 12, Week 24, and Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving LDL-C <70 mg/dL at Week 12, 24, and 52
Percentage of participantsPlaceboBempedoic Acid
Week 129.032.4
Week 2410.232.0
Week 529.528.2
Statistical analysis
  • Placebo vs Bempedoic Acid · Chi-squared · p = <0.001

Adverse events

Collected over Up to approximately 52 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bempedoic Acid13/1,487 (0.9%)216/1,487 (14.5%)792/1,487 (53.3%)
Placebo2/742 (0.3%)104/742 (14%)381/742 (51.3%)
Most frequent serious events
Showing 10 of 230
Most frequent serious events
EventBempedoic AcidPlacebo
Angina unstableCardiac disorders18/148712/742
Angina pectorisCardiac disorders11/14876/742
Coronary artery diseaseCardiac disorders9/14876/742
Acute myocardial infarctionCardiac disorders11/14875/742
Myocardial infarctionCardiac disorders8/14875/742
Non-cardiac chest painGeneral disorders7/14874/742
Atrial fibrillationCardiac disorders7/14871/742
Cardiac failureCardiac disorders5/14873/742
OsteoarthritisMusculoskeletal and connective tissue disorders0/14873/742
SyncopeNervous system disorders3/14873/742
Most frequent other events
Showing 10 of 26
Most frequent other events
EventBempedoic AcidPlacebo
NasopharyngitisInfections and infestations146/148787/742
Urinary tract infectionInfections and infestations70/148747/742
MyalgiaMusculoskeletal and connective tissue disorders89/148745/742
ArthralgiaMusculoskeletal and connective tissue disorders64/148744/742
Upper respiratory tract infectionInfections and infestations72/148731/742
DizzinessNervous system disorders65/148731/742
Muscle spasmsMusculoskeletal and connective tissue disorders62/148720/742
DiarrhoeaGastrointestinal disorders60/148730/742
Back painMusculoskeletal and connective tissue disorders55/148718/742
HypertensionVascular disorders42/148726/742

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBempedoic AcidTotal
Mean66.8 ± 8.6465.8 ± 9.1166.1 ± 8.96
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBempedoic AcidTotal
Female213389602
Male52910991628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBempedoic AcidTotal
Hispanic or Latino112435
Not Hispanic or Latino73114642195
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBempedoic AcidTotal
American Indian or Alaska Native123
Asian81422
Native Hawaiian or Other Pacific Islander022
Black or African American154257
White71614232139
More than one race011
Unknown or Not Reported246
Cardiovascular history: atherosclerotic cardiovascular disease (ASCVD)
Cardiovascular history: atherosclerotic cardiovascular disease (ASCVD)(Participants)PlaceboBempedoic AcidTotal
Yes72714492176
No153954
Cardiovascular history: heterozygous familial hypercholesterolemia (HeFH)
Cardiovascular history: heterozygous familial hypercholesterolemia (HeFH)(Participants)PlaceboBempedoic AcidTotal
Yes235679
No71914322151
History of diabetes
History of diabetes(Participants)PlaceboBempedoic AcidTotal
Yes212425637
No53010631593
History of hypertension
History of hypertension(Participants)PlaceboBempedoic AcidTotal
Yes59411741768
No148314462

13 further baseline measures are reported on the registry.

08

Study locations

104 sites
  • Huntsville, Alabama, United States
  • Cottonwood, Arizona, United States
  • Phoenix, Arizona, United States
  • Canoga Park, California, United States
  • Santa Rosa, California, United States
  • Bridgeport, Connecticut, United States
  • Hartford, Connecticut, United States
  • Atlantis, Florida, United States
  • Boca Raton, Florida, United States
  • Crestview, Florida, United States
  • Crystal River, Florida, United States
  • Daytona Beach, Florida, United States
  • Lake Worth, Florida, United States
  • Miami Lakes, Florida, United States
  • Tampa, Florida, United States
  • Park Ridge, Illinois, United States
  • Iowa City, Iowa, United States
  • Overland Park, Kansas, United States
  • Covington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Minden, Louisiana, United States
  • Monroe, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Auburn, Maine, United States
  • Midland, Michigan, United States
  • Saginaw, Michigan, United States
  • Saint Cloud, Minnesota, United States
  • Tupelo, Mississippi, United States
  • Jefferson City, Missouri, United States
  • Nashua, New Hampshire, United States
  • Bridgewater, New Jersey, United States
  • Cary, North Carolina, United States
  • Mount Airy, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Rocky Mount, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Sandusky, Ohio, United States
  • Willoughby, Ohio, United States
  • Hillsboro, Oregon, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Katy, Texas, United States
  • Kingwood, Texas, United States
  • Orem, Utah, United States
  • Richmond, Virginia, United States
  • Puyallup, Washington, United States
  • Tacoma, Washington, United States
  • Vancouver, British Columbia, Canada
  • Victoria, British Columbia, Canada
  • Gatineau, Ontario, Canada
  • Mississauga, Ontario, Canada
  • Oshawa, Ontario, Canada
  • Peterborough, Ontario, Canada
  • Scarborough, Ontario, Canada
  • Chicoutimi, Quebec, Canada
  • Gatineau, Quebec, Canada
  • Longueuil, Quebec, Canada
  • Montréal, Quebec, Canada
  • Québec, Quebec, Canada
  • Saint-Jean-Sur-Richelieu, Quebec, Canada
  • St-Charles-Borromee, Quebec, Canada
  • Berlin, Germany
  • Bochum, Germany
  • Dresden, Germany
  • Essen, Germany
  • Frankfurt, Germany
  • Leipzig, Germany
  • Muenchen, Germany
  • Amsterdam, Netherlands
  • Arnhem, Netherlands
  • Eindhoven, Netherlands
  • Goes, Netherlands
  • Groningen, Netherlands
  • Hardenberg, Netherlands
  • Leiden, Netherlands
  • Rotterdam, Netherlands
  • Tilburg, Netherlands
  • Venlo, Netherlands
  • Zutphen, Netherlands
  • Gdansk, Poland
  • Gdynia, Poland
  • Katowice, Poland
  • Kraków, Poland
  • Poznań, Poland
  • Puławy, Poland
  • Toruń, Poland
  • Wroclaw, Poland
  • Łowicz, Poland
  • Łódź, Poland
  • Bexhill-on-Sea, United Kingdom
  • Birmingham, United Kingdom
  • Cardiff, United Kingdom
  • Chesterfield, United Kingdom
  • Chichester, United Kingdom
  • Chippenham, United Kingdom
  • Chorley, United Kingdom
  • Glasgow, United Kingdom
  • Hexham, United Kingdom
  • Hull, United Kingdom

Showing the first 100 of 104 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. No abstract available. Erratum In: Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8. Circulation. 2015 Dec 22;132(25):e396. doi: 10.1161/CIR.0000000000000346. PubMed 24222016 ↗
  • Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8. doi: 10.1016/j.jacl.2011.04.003. Epub 2011 Apr 12. PubMed 21600525 ↗
  • Pollex RL, Joy TR, Hegele RA. Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. doi: 10.1517/14728214.13.2.363. PubMed 18537526 ↗
  • Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13. doi: 10.1161/hc3501.095214. PubMed 11535564 ↗
  • Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917. PubMed 30865796 ↗
  • Ballantyne CM, Bays HE, Louie MJ, Smart J, Zhang Y, Ray KK. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 Aug 2;11(15):e024531. doi: 10.1161/JAHA.121.024531. Epub 2022 Aug 2. PubMed 35916348 ↗
  • Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020 Oct 1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314. PubMed 32609313 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Feb 2018, 25 months.

Results were first posted in Apr 2020, 2 years 1 month after primary completion. A results delay was requested in Jul 2018.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2016
First posted
Jan 28, 2016
StartActual
Jan 21, 2016
Primary completionActual
Feb 21, 2018
CompletionActual
Mar 28, 2018
Results delay requested
Jul 23, 2018
Results first posted
Apr 20, 2020
Last update
May 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02666664
Responsible party
Sponsor
First posted
Jan 28, 2016
Start date
Jan 21, 2016
Primary completion
Feb 21, 2018
Completion
Mar 28, 2018
Results posted
Apr 20, 2020
Last update
May 11, 2020

Study contacts

Ron Haberman, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion